

**NEUROENDOCRINE TUMOR RESEARCH  
FOUNDATION, INC.**

Financial Statements

Years Ended December 31, 2025 and 2024

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## CONTENTS

Page

---

Independent Auditors' Report	1-2
Statements of Financial Position	3
Statements of Activities	4
Statements of Functional Expenses	5-6
Statements of Cash Flows	7
Notes to Financial Statements	8-17



## **INDEPENDENT AUDITORS' REPORT**

To the Board of Directors  
Neuroendocrine Tumor Research Foundation, Inc.

### **Opinion**

We have audited the accompanying financial statements of Neuroendocrine Tumor Research Foundation, Inc. (a nonprofit organization), which comprise the statements of financial position as of December 31, 2025 and 2024, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Neuroendocrine Tumor Research Foundation, Inc. as of December 31, 2025 and 2024, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

### **Basis for Opinion**

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibility under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Neuroendocrine Tumor Research Foundation, Inc., and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Responsibilities of Management for the Financial Statements**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Neuroendocrine Tumor Research Foundation, Inc.'s ability to continue as a going concern for a period within one year after the date that the financial statements were available to be issued.

## INDEPENDENT AUDITORS' REPORT (CONTINUED)

### Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgement made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards will, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Neuroendocrine Tumor Research Foundation, Inc.'s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Neuroendocrine Tumor Research Foundation, Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

*Pozerski Hatch & Company, P.C.*

Rockland, Massachusetts  
April 23, 2026

**NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.**  
**STATEMENTS OF FINANCIAL POSITION**  
December 31, 2025 and 2024

	<u>2025</u>	<u>2024</u>
<b>Assets</b>		
Cash and cash equivalents	\$ 2,477,661	\$ 1,613,459
Accounts receivable	2,904	-
Contributions receivable, net	1,291,049	990,391
Prepaid expenses	19,060	27,629
Investments	23,731,261	18,733,446
Right to use asset - operating lease	<u>44,720</u>	<u>12,688</u>
<b>Total assets</b>	<u>\$ 27,566,655</u>	<u>\$ 21,377,613</u>
<b>Liabilities and Net Assets</b>		
Accounts payable and accrued expenses	\$ 295,760	\$ 233,620
Grants payable	4,752,908	4,301,399
Operating lease liability	<u>44,720</u>	<u>6,193</u>
<b>Total liabilities</b>	<u>5,093,388</u>	<u>4,541,212</u>
<b>Net Assets</b>		
Without donor restrictions	5,277,500	1,933,297
With donor restrictions	<u>17,195,767</u>	<u>14,903,104</u>
<b>Total net assets</b>	<u>22,473,267</u>	<u>16,836,401</u>
<b>Total liabilities and net assets</b>	<u>\$ 27,566,655</u>	<u>\$ 21,377,613</u>

The accompanying notes are an integral part of these financial statements.

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## STATEMENTS OF ACTIVITIES

For the Years Ended December 31, 2025 and 2024

	2025			2024		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
<b>Operating activities</b>						
Revenue and support						
Contributions, grants, and sponsorships	\$ 6,633,586	\$ 1,247,208	\$ 7,880,794	\$ 1,967,735	\$ 1,143,954	\$ 3,111,689
Returned grant revenue	17,751	-	17,751	26,171	-	26,171
Interest income	18,613	-	18,613	21,697	-	21,697
Net assets released from restrictions	887,542	(887,542)	-	386,392	(386,392)	-
<b>Total revenue and support</b>	<u>7,557,492</u>	<u>359,666</u>	<u>7,917,158</u>	<u>2,401,995</u>	<u>757,562</u>	<u>3,159,557</u>
<b>Expenses</b>						
Program services:						
Research	3,467,199	-	3,467,199	2,508,191	-	2,508,191
Patient education	404,871	-	404,871	391,343	-	391,343
Outreach and support	83,478	-	83,478	92,938	-	92,938
Total program	<u>3,955,548</u>	<u>-</u>	<u>3,955,548</u>	<u>2,992,472</u>	<u>-</u>	<u>2,992,472</u>
Supporting services:						
Management and general	213,005	-	213,005	246,771	-	246,771
Development	557,008	-	557,008	492,545	-	492,545
Total supporting services	<u>770,013</u>	<u>-</u>	<u>770,013</u>	<u>739,316</u>	<u>-</u>	<u>739,316</u>
<b>Total expenses</b>	<u>4,725,561</u>	<u>-</u>	<u>4,725,561</u>	<u>3,731,788</u>	<u>-</u>	<u>3,731,788</u>
<b>Change in net assets from operating activities</b>	2,831,931	359,666	3,191,597	(1,329,793)	757,562	(572,231)
<b>Nonoperating activities</b>						
Net investment return	<u>512,272</u>	<u>1,932,997</u>	<u>2,445,269</u>	<u>414,685</u>	<u>1,461,193</u>	<u>1,875,878</u>
<b>Change in net assets</b>	3,344,203	2,292,663	5,636,866	(915,108)	2,218,755	1,303,647
<b>Net assets, beginning of year</b>	<u>1,933,297</u>	<u>14,903,104</u>	<u>16,836,401</u>	<u>2,848,405</u>	<u>12,684,349</u>	<u>15,532,754</u>
<b>Net assets, end of year</b>	<u>\$ 5,277,500</u>	<u>\$ 17,195,767</u>	<u>\$ 22,473,267</u>	<u>\$ 1,933,297</u>	<u>\$ 14,903,104</u>	<u>\$ 16,836,401</u>

The accompanying notes are an integral part of these financial statements.

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## STATEMENT OF FUNCTIONAL EXPENSES

For the Year Ended December 31, 2025 (with comparative totals for 2024)

	2025						2024
	Program Services			Supporting Services			Total
	Research	Patient Education	Outreach and Support	Management and General	Development	Expenses	Total Expenses
Salaries	\$ 225,066	\$ 205,719	\$ 71,624	\$ 95,493	\$ 343,840	\$ 941,742	\$ 909,044
Payroll taxes	18,388	16,807	5,852	7,802	28,092	76,941	78,849
Employee benefits	-	16,110	-	3,436	9,055	28,601	31,726
Total personnel expenses	243,454	238,636	77,476	106,731	380,987	1,047,284	1,019,619
Research grants awarded	2,989,009	-	-	-	-	2,989,009	2,164,532
Professional services	18,712	123,149	1,219	66,550	103,728	313,358	229,585
Conferences	180,019	19,877	3,915	-	323	204,134	125,790
Information technology	16,618	1,986	173	13,831	23,903	56,511	34,077
Occupancy	9,705	10,344	-	12,690	17,856	50,595	87,732
Office expenses	365	1,959	695	9,833	20,902	33,754	31,990
Travel	6,956	6,801	-	1,748	4,003	19,508	28,867
Insurance	1,719	1,752	-	1,584	3,504	8,559	7,940
Advertising	642	367	-	38	1,802	2,849	1,656
<b>Total expenses</b>	<b>\$ 3,467,199</b>	<b>\$ 404,871</b>	<b>\$ 83,478</b>	<b>\$ 213,005</b>	<b>\$ 557,008</b>	<b>\$ 4,725,561</b>	<b>\$ 3,731,788</b>

The accompanying notes are an integral part of these financial statements.

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## STATEMENT OF FUNCTIONAL EXPENSES

For the Year Ended December 31, 2024

	Program Services			Supporting Services		Total Expenses
	Research	Patient Education	Outreach and Support	Management and General	Development	
Salaries	\$ 176,847	\$ 205,358	\$ 78,134	\$ 134,577	\$ 314,128	\$ 909,044
Payroll taxes	14,428	15,519	6,155	18,164	24,583	78,849
Employee benefits	693	17,349	642	4,702	8,340	31,726
Total personnel expenses	191,968	238,226	84,931	157,443	347,051	1,019,619
Research grants awarded	2,164,532	-	-	-	-	2,164,532
Professional services	20,449	101,285	-	49,037	58,814	229,585
Conferences	101,075	23,371	-	-	1,344	125,790
Information technology	3,261	244	-	12,949	17,623	34,077
Occupancy	14,825	18,424	7,360	19,568	27,555	87,732
Office expenses	619	816	-	3,256	27,299	31,990
Travel	10,136	6,843	-	2,567	9,321	28,867
Insurance	1,302	1,618	647	1,951	2,422	7,940
Advertising	24	516	-	-	1,116	1,656
<b>Total expenses</b>	<b>\$ 2,508,191</b>	<b>\$ 391,343</b>	<b>\$ 92,938</b>	<b>\$ 246,771</b>	<b>\$ 492,545</b>	<b>\$ 3,731,788</b>

The accompanying notes are an integral part of these financial statements.

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## STATEMENTS OF CASH FLOWS

For the Years Ended December 31, 2025 and 2024

	<u>2025</u>	<u>2024</u>
<b>Cash Flows From Operating Activities</b>		
Change in net assets	\$ 5,636,866	\$ 1,303,647
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities		
Net realized and unrealized gains on investments	(1,925,968)	(1,383,048)
Amortization of right to use asset	40,490	75,691
Change in discount on contributions receivable	30,972	19,054
Change in discount on grants payable	(25,991)	(54,524)
(Increase) decrease in assets		
Accounts receivable	(2,904)	-
Contributions receivable	(331,630)	(496,177)
Prepaid expenses	8,569	(10,212)
Increase (decrease) in liabilities		
Accounts payable and accrued expenses	62,140	16,409
Grants payable	477,500	(443,992)
Operating lease liability	(33,995)	(77,170)
<b>Net cash provided by (used by) operating activities</b>	<u>3,936,049</u>	<u>(1,050,322)</u>
<b>Cash Flows From Investing Activities</b>		
Purchases of investments	(3,582,307)	(539,513)
Proceeds from sales of investments	510,460	1,646,686
<b>Net cash provided by (used by) investing activities</b>	<u>(3,071,847)</u>	<u>1,107,173</u>
Net change in cash and cash equivalents	864,202	56,851
<b>Cash and cash equivalents, beginning of year</b>	<u>1,613,459</u>	<u>1,556,608</u>
<b>Cash and cash equivalents, end of year</b>	<u>\$ 2,477,661</u>	<u>\$ 1,613,459</u>
<b>Supplemental Disclosure of Non-Cash Financing Activities</b>		
Acquisition of right to use asset with operating lease obligation	<u>\$ 72,522</u>	<u>\$ -</u>

The accompanying notes are an integral part of these financial statements.

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### NOTE 1 – NATURE OF THE ORGANIZATION

#### Organization

Neuroendocrine Tumor Research Foundation, Inc. (the Foundation) is a nonprofit corporation organized under Massachusetts General Laws Chapter 180. It is also a 501(c)(3) organization under the Internal Revenue Code of 1986 as amended. Its primary purpose is to support neuroendocrine cancer research. It accomplishes this by funding breakthrough scientific research into neuroendocrine cancer. In addition, it is committed to supporting patients, families, friends and caregivers by providing them with up-to-date information and resources. The Foundation is predominantly supported by donors throughout the United States.

### NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### Basis of Presentation

The Foundation's financial statements are presented in conformity with U.S. generally accepted accounting principles and have been prepared on the accrual basis of accounting.

#### Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the Foundation to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those differences could be material.

#### Net Asset Classifications

Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

*Net Assets without Donor Restrictions* – Net assets available for use in general operations and not subject to donor restrictions.

*Net Assets with Donor Restrictions* – Net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates certain resources be maintained in perpetuity. The Foundation reports contributions restricted by donors as increases in net assets without donor restrictions if the restrictions expire (that is, when a stipulated time restriction ends or purpose restriction is accomplished) in the reporting period in which the revenue is recognized. All other donor-restricted contributions are reported as increases in net assets with donor restrictions, depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions.

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### Operations

The statements of activities report the changes in net assets from operating and nonoperating activities. Operating expenses consist of those items attributable to the Foundation's primary mission and interest income on the Foundation's undesignated operating cash. Investment returns are classified as nonoperating activities. Gifts to the endowment and other gifts and grants not directed to operations are also classified as nonoperating activities.

#### Cash and Cash Equivalents

The Foundation considers cash and cash equivalents to be currency on hand or deposits and all highly liquid investments with maturities of three months or less when acquired.

The Foundation maintains its cash balances at highly rated financial and investment institutions, which at times may exceed insured limits. The Foundation monitors its exposure associated with cash and cash equivalents and has not experienced any losses in such accounts.

#### Contributions and Contributions Receivable

Contributions, including unconditional promises to give, are recognized as revenues in the period received. Contributions receivable that are, in effect, "unconditional promises to give" are recorded at the present value of future cash flows. Conditional promises to give are not recognized until they become unconditional, that is, at the time when the conditions on which they depend are substantially met. Contributions of assets other than cash are recorded at their estimated fair value. Contributions to be received after one year are discounted at an appropriate discount rate. Amortization of discount is recorded as additional contribution revenue in accordance with donor-imposed restrictions, if any, on the contributions.

An allowance for uncollectible contributions receivable is provided based upon management's judgment of potential un-collectability. This determination includes such factors as prior collection history, type of contribution and nature of fundraising activity. At December 31, 2025 and 2024, there was no allowance for doubtful accounts.

#### Leases

The Foundation leases space under an operating lease. The Foundation determines whether an arrangement is a lease at its inception. For leases with terms greater than twelve months, the Foundation records the related asset and obligation at the present value of lease payments over the term.

#### Investments

The Foundation records investment purchases at cost, or if donated, at fair value on the date of donation. Thereafter, investments are reported at their fair values in the statements of financial position.

# **NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.**

## **NOTES TO FINANCIAL STATEMENTS**

### **NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

#### **Investments (Continued)**

Net investment return (loss) is reported in the statements of activities and consists of interest and dividend income, net realized and unrealized gains and losses, less external and direct internal investment expenses. Net realized and unrealized gains and losses are reflected in the statements of activities under the net assets with or without donor restrictions captions, as applicable. Income derived from the investment of endowment funds is reported as an increase in net assets with donor restriction if the terms of the underlying gift or relevant state law impose restrictions of the use of the income or net gains. Income and net gains on board designated and other funds are reported as an increase in net assets without donor restrictions.

Investment securities, in general, are exposed to various risks, such as interest rate, credit and overall market volatility. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term, and that such changes could materially affect the amounts reported on the statements of financial position.

#### **Donated Services and In-Kind Contributions**

The Foundation may record various types of in-kind support including professional services, advertising, and materials. Contributed services are recognized if the services received (a) create or enhance long-lived assets or (b) require specialized skills, are provided by individuals possessing those skills, and (c) would typically need to be purchased if not provided by donations. Contributions of tangible assets are recognized at fair market value when received. There were no donated services or in-kind contributions during the years ended December 31, 2025 and 2024.

#### **Revenue Recognition**

The Foundation recognizes revenue at an amount that reflects the consideration to which the Foundation expects to be entitled in exchange for transferring goods or services to its customers using the following five-step process:

1. Identify the contract with the customer
2. Identify the performance obligation in the contract
3. Determine the transaction price
4. Allocate the transaction price to the performance obligations in the contract
5. Recognize revenue when the Foundation satisfies a performance obligation

The Foundation recognizes the refund of grants at a point in time when the refund is known by management and agreed upon with the awardee.

# **NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.**

## **NOTES TO FINANCIAL STATEMENTS**

### **NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

#### **Functional Allocation of Expenses**

The costs of program and supporting services activities have been summarized on a functional basis in the statements of activities. The statements of functional expenses present the natural classification detail of expenses by function. Expenses are charged to each program based on direct expenditures incurred. Categories of expenses that are attributed to more than one program or supporting function require allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries, employee benefits, payroll taxes, professional services, information technology, occupancy, office expenses, insurance, and others. These expenses are allocated based on the estimates of the time and effort expended for each program, administrative, and development function.

#### **Tax Status**

The Foundation is an exempt organization under Internal Revenue Code Section 501(c)(3) and is not considered a private foundation. The Foundation is also exempt from Massachusetts income taxes.

The Foundation has identified its tax status as a tax-exempt entity as a tax position; however, it has determined that such tax position does not result in an uncertainty requiring recognition. The Foundation is not currently under examination by any taxing jurisdiction. Its Federal and state tax returns are generally open for examination for the past three years.

#### **Reclassifications**

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the previously reported changes in net assets.

#### **Subsequent Events**

We have evaluated subsequent events through April 23, 2026, which is the date the financial statements were available to be issued.

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### NOTE 3 – LIQUIDITY AND AVAILABILITY

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the statement of financial position date, consists of the following:

	<u>2025</u>	<u>2024</u>
Cash and cash equivalents	\$ 2,477,661	\$ 1,613,459
Accounts receivable	2,904	-
Contributions receivable, net	1,291,049	990,391
Operating investments	<u>8,441,336</u>	<u>5,404,296</u>
Total	12,212,950	8,008,146
Less amount unavailable for general expenditure within one year:		
Net asset with restrictions	<u>(1,933,620)</u>	<u>(1,573,954)</u>
Financial assets available for general expenditure within one year	<u>\$ 10,279,330</u>	<u>\$ 6,434,192</u>

As part of its liquidity management plan, the Foundation maintains cash in excess of daily requirements in short-term investments, money market funds, and savings accounts.

### NOTE 4 – CONTRIBUTIONS RECEIVABLE

Contributions receivable consists of unconditional promises to give from individuals and foundation donors. These receivables are considered low-risk because a significant portion represents commitments from either large, well-established foundations or individual donors with a long-term relationship with the Foundation.

	<u>2025</u>	<u>2024</u>
Amounts due in:		
In one year or less	\$ 741,075	\$ 771,945
In one to five years	600,000	237,500
	<u>1,341,075</u>	<u>1,009,445</u>
Less: unamortized discount	<u>(50,026)</u>	<u>(19,054)</u>
Contributions receivable	<u>\$ 1,291,049</u>	<u>\$ 990,391</u>

The discount rate used to present value the estimated cash flows from pledges receivable was 3.55% and 4.27% at December 31, 2025 and 2024, respectively.

### NOTE 5 – INVESTMENTS

Accounting standards establish a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy consists of three broad levels: Level 1 inputs consist of unadjusted quoted prices in active markets for identical assets and have the highest priority; Level 2 inputs consist of observable inputs other than quoted prices for identical assets; and Level 3 inputs have the lowest priority. The Foundation uses appropriate valuation techniques based on the available inputs to measure the fair value of its investments. When available, the Foundation measures fair value using Level 1 inputs because they generally provide the most reliable evidence of fair value. Level 3 inputs are used only when Level 1 or Level 2 inputs are not available.

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### NOTE 5 – INVESTMENTS (CONTINUED)

As of December 31, 2025 and 2024, the Foundation's investment portfolio consists of the following:

	<b>2025</b>	<b>2024</b>
	<b>Fair Value</b>	<b>Fair Value</b>
	<b>(Level 1)</b>	<b>(Level 1)</b>
Mutual funds – equity	\$ 13,335,128	\$ 10,806,214
Mutual funds – fixed income	10,396,133	7,927,232
Total	<u>\$ 23,731,261</u>	<u>\$ 18,733,446</u>

Mutual funds are valued at the closing price recorded in the active market in which the individual securities are traded.

The following schedule summarizes investment return for the years ended December 31, 2025 and 2024:

	<b>2025</b>	<b>2024</b>
Interest and dividends	\$ 582,307	\$ 539,516
Investment fees	(63,006)	(46,686)
Net realized and unrealized gains	1,925,968	1,383,048
Total	<u>\$ 2,445,269</u>	<u>\$ 1,875,878</u>

As of December 31, 2025 and 2024, the Foundation's investments were held for the following purposes:

	<b>2025</b>	<b>2024</b>
Operating	\$ 8,441,336	\$ 5,404,296
Endowment	15,289,925	13,329,150
Total	<u>\$ 23,731,261</u>	<u>\$ 18,733,446</u>

### NOTE 6 – RESEARCH GRANTS PAYABLE

The Foundation annually awards single-year and multi-year research grants to fund scientific research of neuroendocrine cancer. Payments are made according to the terms of the grant agreement, which are typically according to pre-set dates or upon reaching certain milestones. All grants are expensed upon approval by the Board of Directors as the terms and conditions of the awards are considered to be administrative in nature. Changes in grants payable are as follows:

	<b>2025</b>	<b>2024</b>
Grants payable at beginning of year, net	\$ 4,301,399	\$ 4,799,915
Grants awarded	3,015,000	2,219,056
Payments made	(2,519,749)	(2,636,877)
Return of previously awarded grant	(17,751)	(26,171)
Change in discount on long-term grants payable	(25,991)	(54,524)
Grants payable at end of year, net	<u>\$ 4,752,908</u>	<u>\$ 4,301,399</u>

Long-term grants payable are discounted to present value using risk-free federal adjusted rate of approximately 3.55% and 4.27% at December 31, 2025 and 2024, respectively. The discount on grants payable was \$183,148 and \$157,157 at December 31, 2025 and 2024, respectively.

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### NOTE 6 – RESEARCH GRANTS PAYABLE (CONTINUED)

Grants payable at December 31, 2025, prior to discounting, are scheduled to be distributed as follows:

2026	\$	2,820,056
2027	\$	1,306,000
2028	\$	490,000
2029	\$	160,000
2030	\$	160,000

### NOTE 7 – ENDOWMENT FUNDS

The Foundation's endowment consists of mutual funds that have been restricted by a donor to be maintained in perpetuity, established to support the achievement of the Foundation's mission. As required by accounting principles generally accepted in the United States of America, net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

#### *Interpretation of Relevant Law*

The Board of Directors of the Foundation has interpreted Massachusetts Uniform Prudent Management of Institutional Funds Act (UPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment fund, absent explicit donor stipulations to the contrary. Consequently, the Foundation classifies the original value of gifts donated to the endowment, and any additional amounts restricted by the donor, to be held in perpetuity within net assets with donor restrictions. Investment income and cumulative appreciation (net unrealized and realized gains) of the donor-restricted endowment fund are also classified as net assets with donor restriction and are included in the calculation for distribution amounts (as described more fully in the Spending Policy section below) in accordance with donor stipulations.

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor or UPMIFA requires the Foundation to retain as a fund of an explicitly stated duration. In accordance with accounting principles generally accepted in the United States of America, deficiencies of this nature are to be reported as reductions in net assets with donor restrictions.

Subject to the intent of the donor expressed in the gift instrument, the assets in an endowment fund shall be donor-restricted assets until appropriated for expenditure by the Foundation. In making a determination to appropriate or accumulate, the Foundation considers the following factors:

1. The duration and preservation of the endowment fund;
2. The purposes of the Foundation and the donor-restricted endowment fund;
3. General economic conditions;
4. The possible effect of inflation or deflation;
5. The expected total return from income and the appreciation of investments;
6. Other resources of the Foundation; and
7. The investment policy of the Foundation.

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### NOTE 7 – ENDOWMENT FUNDS (CONTINUED)

#### *Return Objectives and Risk Parameters*

The Foundation has adopted investment and spending policies for endowment assets with the objective of preserving the long-term, real purchasing power of assets while ensuring the ability of the Foundation to meet short-term grant funding commitments. Fund assets earmarked for short-term distribution to fulfill donor guidelines may be more conservative with a higher cash position, while funds dedicated to the long-term endowment may have different investment goals and anticipated returns.

#### *Strategies Employed for Achieving Objectives*

Fund assets will be managed as a balanced portfolio composed of two major components: an equity portion and a fixed income portion. The expected role of equity investments will be to maximize the long-term real growth of portfolio assets, while the role of fixed income investments will be to generate current income, provide for more stable periodic returns, and provide some protection against a prolonged decline in the market value of portfolio equity investments.

#### *Spending Policy*

Based on an amended agreement with the donor, effective November 25, 2021, the Foundation is limited in spending from 2022 – 2024 to previously awarded grants totaling \$1,200,000. Beginning in 2025, the Foundation can spend as much of the income and realized growth of the endowment as it deems prudent, so long as at end of the calendar year, the balance in the fund is at least equal to \$10,380,000. The Foundation has not yet taken a spend withdrawal.

Changes in endowment funding during fiscal year 2025 and 2024 are:

	<u>2025</u>	<u>2024</u>
Endowment funds invested, beginning of year	\$ 13,329,150	\$ 11,867,957
Interest and dividends, net of fees	366,500	310,449
Net realized and unrealized gains	1,594,275	1,150,744
Endowment funds invested, end of year	<u>\$ 15,289,925</u>	<u>\$ 13,329,150</u>

Included in the above, is \$27,778 of accrued investment management fees that have not been withdrawn from the investment accounts as of December 31, 2025.

# NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### NOTE 8 – NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions at December 31, 2025 and 2024 were restricted for the following purposes:

	<u>2025</u>	<u>2024</u>
Funds held for specific purposes or time periods:		
Specific research projects	\$ 670,575	\$ 674,313
Passage of time	1,174,474	649,641
Patient guide and Thrivership resources	88,571	250,000
	<u>1,933,620</u>	<u>1,573,954</u>
Donor restricted endowment funds – corpus	10,380,000	10,380,000
Donor restricted endowment funds – appreciation	4,882,147	2,949,150
Total donor restricted endowment funds	<u>15,262,147</u>	<u>13,329,150</u>
Total net assets with donor restriction	<u>\$ 17,195,767</u>	<u>\$ 14,903,104</u>

Net assets were released from restrictions during December 31, 2025 and 2024 as follows:

	<u>2025</u>	<u>2024</u>
Satisfaction of purpose restrictions	\$ 887,542	\$ 386,392

### NOTE 9 – LEASES

The Foundation leased office space under a non-cancellable operating lease, which was signed on December 3, 2019, with a lease term from February 1, 2020 through March 1, 2025. Upon expiration of this lease, the Foundation entered into a new operating lease for office space, which was signed on January 6, 2025, with a lease term from March 16, 2025 through February 28, 2027. Operating lease costs for office space totaled \$50,919 and \$81,066 for the years ending December 31, 2025 and 2024, respectively. Fixed rental payments under these leases for the remaining term of the leases are as follows:

Year ending December 31:

	<u>2025</u>	<u>2024</u>
2025	\$ -	\$ 6,209
2026	39,168	-
2027	6,528	-
Total future minimum lease payments	<u>45,696</u>	<u>6,209</u>
Less imputed interest	<u>(976)</u>	<u>(16)</u>
Total	<u>\$ 44,720</u>	<u>\$ 6,193</u>

The Foundation used the private company option of using the risk-free interest rate to determine the present value lease assets and liability. The rate used was 3.47% and the weighted average term of the lease was 14 months at December 31, 2025. As of December 31, 2025 and 2024, the right-of-use asset recorded under the operating leases amounted to \$72,522 and \$237,875, respectively, with related accumulated amortization of \$27,802 and \$225,187, respectively. Amortization expense on the right to use asset was \$40,490 and \$75,691 for the years ended December 31, 2025 and 2024, respectively.

# **NEUROENDOCRINE TUMOR RESEARCH FOUNDATION, INC.**

## **NOTES TO FINANCIAL STATEMENTS**

### **NOTE 10 – CONCENTRATIONS OF REVENUE AND SUPPORT**

The Foundation receives substantial contributions. Contributions from three and one donors represented 67% and 13% of total contributions, grants and sponsorships for the years ended December 31, 2025 and 2024, respectively.

Receivables from three and two donors comprised 93% and 65% of contributions receivable at December 31, 2025 and 2024, respectively.

### **NOTE 11 – EMPLOYEE BENEFIT PLAN**

The Foundation participates in a qualified 401k deferred income plan. All employees are eligible to contribute a portion of their compensation to the plan in accordance with plan provisions. The Foundation does not match participant contributions.